[#item_full_content] A botanically derived, non-opioid pain treatment made from cannabis is moving through regulatory review in Europe and the United States, adding to growing evidence that supported the FDA’s 2024 recommendation to reschedule cannabis to Schedule III. This pharmaceutical-grade therapy, known as Exilby and developed under the investigational name VER-01, is an oral liquid-drop formulation containing 
Read More
Exilby: FDA Fast-Tracks Cannabis-Derived Painkiller Disrupting Multi-Billion-Dollar Opioid Industry: Vicente LLP
ByPot Shop News
August 4, 2026